Hammett-Stabler Catherine A, Geis Diane Ciuffetti, Ritchie James C, Papadea Christine
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Methods Mol Biol. 2010;603:379-87. doi: 10.1007/978-1-60761-459-3_37.
Therapeutic drug management of patients receiving mycophenolic mofetil or mycophenolate sodium using mycophenolic acid (MPA) concentrations is controversial. Considered to be less toxic compared to many of the other drugs used in immunosuppression regimens, MPA is not tolerated by all patients. For these patients, monitoring is useful in achieving desired therapeutic targets, reducing adverse effects, and individualizing dosing. We describe an LC-MS-MS that permits the measurement of MPA and 7-O-glucuronide mycophenolic acid (MPAG) in serum or plasma.
使用霉酚酸（MPA）浓度对接受吗替麦考酚酯或麦考酚钠治疗的患者进行治疗药物管理存在争议。与免疫抑制方案中使用的许多其他药物相比，MPA被认为毒性较小，但并非所有患者都能耐受。对于这些患者，监测有助于实现理想的治疗目标、减少不良反应并实现个体化给药。我们描述了一种液相色谱-串联质谱法，可用于测定血清或血浆中的MPA和7-O-葡萄糖醛酸霉酚酸（MPAG）。
